Lumos Lands US$250k Order Under 3-Year Manufacturing Deal With Mold Tech Firm
Lumos Diagnostics secures three-year Micro-Pak manufacturing contract with US$250,000 initial order
Lumos Diagnostics Holdings Ltd (ASX: LDX) has converted four years of development partnership into an ongoing Lumos Diagnostics Micro-Pak manufacturing contract, with the company receiving a US$250,000 first purchase order under a three-year supply agreement. The contract represents a commercial milestone for Lumos’ Commercial Services Division, converting prior research and development investment into recurring manufacturing revenue.
The agreement with Micro-Pak covers production of the Mold Analyzer system, comprising rapid test cassettes and Lumos’ proprietary digital camera readers. The three-year contract includes automatic one-year renewal periods, providing potential for sustained manufacturing revenue as Micro-Pak scales commercial operations.
The Mold Analyzer system explained
The Mold Analyzer is a point-of-care testing system designed to detect mold contamination across industrial supply chains and consumer environments. Traditional mold detection requires laboratory analysis with extended turnaround times, whereas point-of-care testing enables on-site results for both professional supply chain use and consumer home testing.
The system comprises three integrated components: a rapid test cassette developed by Lumos for Micro-Pak, a digital camera reader, and a custom mobile application. The Mold Analyzer rapid test cassette is reported to be the first in the world to detect 56 mold species, providing broad coverage for real-world environments.
The technology offers two configurations depending on end-user requirements. Professional users can deploy the reader-based system for full traceability of mold testing across manufacturing supply chains, whilst the system is also configurable as a stand-alone visual-read test for low-cost consumer testing in home environments. This dual-market applicability expands the addressable market for Micro-Pak, which in turn supports sustained manufacturing demand for Lumos.
When big ASX news breaks, our subscribers know first
What Lumos manufactures under the agreement
Lumos’ manufacturing scope under the Micro-Pak contract focuses on specific system components rather than the complete integrated solution. The Commercial Services Division will supply:
- Mold Analyzer rapid test cassettes
- Lumos proprietary digital camera readers
- Ongoing production supply (not one-time manufacturing run)
Contract manufacturing provides higher-margin recurring revenue compared to one-off development fees, with potential for volume growth as Micro-Pak achieves commercial traction. The agreement builds on previous contract development work conducted over four years, during which Lumos developed the Mold Analyzer from concept through to market launch.
Who is Micro-Pak and why it matters for Lumos
Micro-Pak is a global leader in mold and moisture prevention products that protect goods across industrial supply chains. The Mold Analyzer builds on Micro-Pak’s existing sample-collection and laboratory analysis service, extending the company’s capabilities into rapid on-site testing.
The partnership provides reference value for Lumos when pursuing other contract manufacturing clients, demonstrating the company’s ability to develop novel diagnostic systems for established industry players. More information on Micro-Pak can be viewed at www.micropakltd.com, with product-specific details available at www.moldanalyzer.com.
CEO commentary on the contract win
Doug Ward, CEO
“The signing of this contract manufacturing agreement further validates the services component of the broader Lumos business. This agreement demonstrates Lumos’ ability to convert substantial contract development programs into ongoing contract manufacturing agreements. We are proud to have worked with Micro-Pak to develop the Mold Analyzer from concept through to market launch. This first purchase order marks the start of commercial-scale manufacturing for Micro-Pak and represents valuable revenue for Lumos’ services business.”
Management explicitly positions the Micro-Pak contract as a template for future wins, with development relationships converting to manufacturing revenue as products reach commercial launch.
Contract terms and revenue outlook
The commercial agreement provides Lumos with defined revenue visibility over a three-year base period, with automatic renewal provisions extending potential manufacturing supply beyond the initial term.
| Contract Element | Detail |
|---|---|
| Initial Purchase Order | US$250,000 |
| Contract Term | Three years |
| Renewal | Automatic one-year periods |
| Prior Development Period | Four years |
The initial US$250,000 order represents the start of commercial-scale production, with potential for larger future orders as Micro-Pak’s market penetration increases. Auto-renewal terms suggest the possibility of multi-year revenue visibility if the Mold Analyzer achieves commercial traction in professional and consumer markets.
The next major ASX story will hit our subscribers first
What this means for Lumos’ services business
The Micro-Pak manufacturing contract reinforces the Commercial Services Division’s strategic positioning within Lumos’ broader business model. The company operates across three revenue streams: proprietary Lumos-branded diagnostic tests, custom development programmes, and contract manufacturing.
This agreement contributes to the services portfolio in three specific ways:
- Validates the development-to-manufacturing conversion model established over four years of collaboration
- Adds recurring manufacturing revenue with potential for volume growth tied to Micro-Pak’s commercial success
- Demonstrates capability in non-medical applications, diversifying beyond traditional healthcare diagnostics into industrial and consumer markets
The diversification beyond healthcare diagnostics into mold detection for supply chain and consumer applications broadens Lumos’ addressable market and reduces concentration risk. Contract manufacturing for established industry partners provides reference credentials that may support business development efforts with other potential clients seeking custom diagnostic solutions.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving healthcare and biotech announcements delivered straight to your inbox the moment they drop.